MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/650/0.01/20.12.24 | Market Closed - Börse Stuttgart 19:22:06 07/06/2024 BST | ||
| 0.093 EUR | +5.68% |
|
| Current month | +34.78% | ||
| 1 month | +52.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.093 | +5.68% |
| 06/06/24 | 0.088 | -1.12% |
| 05/06/24 | 0.089 | +5.95% |
| 04/06/24 | 0.084 | +9.09% |
| 03/06/24 | 0.077 | +11.59% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 07:22 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME6ZWJ |
| ISIN | DE000ME6ZWJ8 |
| Date issued | 16/01/2024 |
| Strike | 650 $ |
| Maturity | 20/12/2024 (195 Days) |
| Parity | 100 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.115 € |
|---|---|
| Lowest since issue | 0.05 € |
| Spread | 0.01 € |
| Spread % | 9.90% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
